NCT01358903View on ClinicalTrials.gov

A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Neoplasms
Interventions
DRUG

RO5429083

Cohorts receiving multiple escalating doses iv

DRUG

RO5429083

Cohorts receiving 89Zr-labelled RO5429083 plus RO5429083, followed by RO5429083 until disease progression

Trial Locations (6)

31059

Toulouse

75231

Paris

77030

Houston

98109

Seattle

1081 HV

Amsterdam

6500 HB

Nijmegen

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01358903 - A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors | Biotech Hunter | Biotech Hunter